IRLAB Therapeutics AB
STO:IRLAB A
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.9
19.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
IRLAB Therapeutics AB
IRLAB Therapeutics AB
PP&E Net
IRLAB Therapeutics AB
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IRLAB Therapeutics AB
STO:IRLAB A
|
PP&E Net
kr6.7m
|
CAGR 3-Years
16%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
PP&E Net
kr59.4m
|
CAGR 3-Years
89%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
PP&E Net
kr40.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
PP&E Net
kr522.4m
|
CAGR 3-Years
118%
|
CAGR 5-Years
100%
|
CAGR 10-Years
N/A
|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
PP&E Net
kr4.9m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
PP&E Net
kr1.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
IRLAB Therapeutics AB
Glance View
IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
See Also
What is IRLAB Therapeutics AB's PP&E Net?
PP&E Net
6.7m
SEK
Based on the financial report for Dec 31, 2023, IRLAB Therapeutics AB's PP&E Net amounts to 6.7m SEK.
What is IRLAB Therapeutics AB's PP&E Net growth rate?
PP&E Net CAGR 5Y
41%
Over the last year, the PP&E Net growth was -17%. The average annual PP&E Net growth rates for IRLAB Therapeutics AB have been 16% over the past three years , 41% over the past five years .
You don't have any saved screeners yet
